Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease

Rhea-AI Summary

Adaptive Biotechnologies (Nasdaq: ADPT) announced that Dr. Harlan Robins, Chief Scientific Officer and Co‑Founder, and Susan Bobulsky, Chief Commercial Officer, MRD, will participate in a Jefferies fireside chat on Minimal Residual Disease (MRD) in hematology/oncology with a deep dive into the clonoSEQ assay technology.

The session is scheduled for Thursday, December 11, 2025, 2:00 p.m. to 3:00 p.m. ET. Interested parties may contact their Jefferies sales representative for participation details.

News Market Reaction – ADPT

+5.92%

40 alerts

+5.92% Session close to close

+4.5% Peak in 28 hr 57 min

$2.48B Market Cap

0.8x Rel. Volume

In the Dec 10 session, ADPT gained 5.92%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.5% during that session. Our momentum scanner triggered 40 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.9% in the session following this news. A strong positive reaction aligns with pri...

Analysis

The stock moved +5.9% in the session following this news. A strong positive reaction aligns with prior responses to MRD-related updates, such as the +9.94% move on ASH abstracts and gains after the Q3 2025 results and raised MRD guidance. However, recent Form 4 filings show notable insider selling, which could temper enthusiasm if investors question sustainability. Past conference announcements have produced smaller moves, so outsized strength after a fireside chat might prove sensitive to shifts in sentiment or news flow.

Key Figures

Q3 2025 revenue: $94.0M Revenue ex-Genentech: $60.2M MRD revenue: $56.8M +5 more

8 metrics

Q3 2025 revenue $94.0M Reported Q3 2025 results release

Revenue ex-Genentech $60.2M Q3 2025 revenue excluding $33.7M Genentech amortization

MRD revenue $56.8M Q3 2025 MRD revenue, +52% YoY

clonoSEQ volume 27,111 tests Q3 2025 clonoSEQ test volume, +38% YoY

MRD Adjusted EBITDA $7.0M Q3 2025 MRD segment Adjusted EBITDA

Company Adjusted EBITDA $28.0M Q3 2025 company-wide Adjusted EBITDA

Cash & securities $216.8M Cash and marketable securities at Q3 2025

MRD guidance $202–$207M Raised full-year 2025 MRD revenue guidance

Historical Context

5 past events · Latest: Nov 24 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Nov 24	Scientific conference data	Positive	+9.9%	ASH meeting featuring 89 clonoSEQ MRD abstracts and 36 orals.
Nov 06	Investor conferences	Neutral	-5.0%	Planned presentations at Jefferies and Piper Sandler healthcare conferences.
Nov 05	Q3 2025 earnings	Positive	+4.0%	Strong MRD growth, positive EBITDA metrics and raised MRD guidance.
Oct 15	Earnings scheduling	Neutral	+0.9%	Announcement of Q3 2025 results date and webcast details.
Aug 27	Investor conference	Neutral	+2.6%	Planned fireside chat at Morgan Stanley healthcare conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Stock has reacted positively to MRD/earnings updates, while routine conference participation has produced smaller, mixed moves.

Recent Company History

Over the last six months, Adaptive Biotechnologies has highlighted growing MRD momentum and increasing scientific visibility. The Q3 2025 earnings release on Nov 5 showed higher revenue and raised MRD guidance, followed by an ASH-related MRD abstract update on Nov 24, which coincided with a +9.94% move. Multiple conference and fireside chat announcements generated smaller price changes, suggesting investors focus more on data and financial updates than routine appearances. Today’s MRD-focused Jefferies chat fits this ongoing communication pattern.

Key Terms

minimal residual disease, hematology/oncology, assay

3 terms

minimal residual disease medical

"to discuss Minimal Residual Disease (MRD) in Hematology/Oncology"

Minimal residual disease (MRD) is the tiny number of cancer cells that remain in the body after treatment, often too few to show up on standard scans but detectable with very sensitive tests. For investors, MRD is important because it predicts the risk of relapse and can determine whether a therapy is seen as effective, influences regulatory and reimbursement decisions, and affects the size and timing of a drug’s market opportunity—like spotting the last weeds that can make a garden regrow if not removed.

hematology/oncology medical

"Minimal Residual Disease (MRD) in Hematology/Oncology with deep dive"

Hematology/oncology is the medical specialty that diagnoses and treats blood disorders (like anemia or blood clotting problems) and cancers. Investors care because breakthroughs, drug approvals, or clinical setbacks in this area can significantly change a company’s revenue outlook—think of it as a product roadmap where a new effective therapy can unlock large demand, while failed trials can erase expected future sales. Progress here directly affects valuation for companies focused on blood and cancer treatments.

assay medical

"with deep dive into the clonoSEQ assay technology"

An assay is a laboratory test that detects or measures how much of a specific substance is present or how well something performs, like measuring a drug’s concentration, a material’s purity, or a biomarker’s level. For investors, assay results act like a thermometer or quality check: they provide objective evidence about a product’s effectiveness, safety, or manufacturing consistency, and can strongly influence regulatory approval, market acceptance, and company valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEATTLE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced Dr. Harlan Robins, Chief Scientific Officer and Co-Founder and Susan Bobulsky, Chief Commercial Officer, MRD will be participating in a Jefferies fireside chat to discuss Minimal Residual Disease (MRD) in Hematology/Oncology with deep dive into the clonoSEQ assay technology. The call will take place on Thursday, December 11, 2025, from 2:00 p.m. to 3:00 p.m. Eastern Time. Interested parties may reach out to their Jefferies sales representative for details.

About Adaptive Biotechnologies

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com

FAQ

When will Adaptive Biotechnologies (ADPT) present on MRD at the Jefferies fireside chat?

Adaptive will present on December 11, 2025, from 2:00 p.m. to 3:00 p.m. ET.

Who from Adaptive Biotechnologies (ADPT) will speak about clonoSEQ at the Jefferies event?

Speakers are Dr. Harlan Robins (Chief Scientific Officer and Co‑Founder) and Susan Bobulsky (Chief Commercial Officer, MRD).

What topic will Adaptive Biotechnologies (ADPT) cover in the Jefferies fireside chat?

The discussion will focus on Minimal Residual Disease (MRD) in hematology/oncology and a deep dive into the clonoSEQ assay technology.

How can investors access the Adaptive Biotechnologies (ADPT) Jefferies fireside chat on December 11, 2025?

Interested parties should reach out to their Jefferies sales representative for access and participation details.

Will the Jefferies fireside chat on MRD include technical detail on clonoSEQ for ADPT investors?

Yes, the event is described as a deep dive into clonoSEQ assay technology, indicating technical discussion.

Is the Jefferies fireside chat for Adaptive Biotechnologies (ADPT) a public webcast on December 11, 2025?

The announcement directs interested parties to contact Jefferies sales representatives for details, rather than stating a public webcast.